The economic impact of acute coronary syndrome on length of stay: an analysis using the Healthcare Cost and Utilization Project (HCUP) databases.

Abstract:

OBJECTIVE:To assess the economic impact of initial and repeat hospitalizations associated with acute coronary syndrome (ACS) over 1 year (2009). DESIGN AND METHODS:National- and state-level data on length of stay (LOS) and related charges for ACS-associated hospital admissions were assessed using two Healthcare Utilization Project databases. The first, the Nationwide Inpatient Sample (NIS), provided clinical and resource use information from ∼8 million hospital stays, representing a 20% stratified sample of ∼40 million annual hospital stays in the US in 2009. The second, the State Inpatient Databases, provided 100% of inpatient data from nine states that included both patient age and linked information on multiple patient admissions within the same calendar year. For patients with repeat admissions, the LOS, primary diagnosis, and total charges between the first and subsequent admissions were evaluated. All patients≥18 years of age with at least one diagnosis of ACS, defined using the International Classification of Diseases, 9th Revision, were included (code 410.xx [except 410.x2], 411.1x and 411.8x). Variables evaluated for each discharge included demographics, cardiovascular events and procedures, LOS, discharge status, and total charges. RESULTS:The NIS reported 1,437,735 discharges for ACS in 2009. In this dataset, mean LOS for an initial ACS event was 5.56 days. Patients>65 years of age had the highest numbers of admissions; this group also had the most comorbidities. Approximately 40% of ACS patients with data on repeat visits had more than one admission, >70% of these within 2 months of the primary discharge. Mean charges were $71,336 for the first admission and $53,290 for the second admission. CONCLUSION:Despite a variety of new therapies to prevent ACS, it remains a common condition. Better therapies are called for if the clinical and cost burden of ACS is to be alleviated.

journal_name

J Med Econ

authors

LaMori JC,Shoheiber O,Dudash K,Crivera C,Mody SH

doi

10.3111/13696998.2014.885907

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

191-7

issue

3

eissn

1369-6998

issn

1941-837X

journal_volume

17

pub_type

杂志文章
  • Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey.

    abstract:OBJECTIVES:Non-severe nocturnal hypoglycemic events (NSNHEs) may have a major impact on patients. The objective was to determine how NSNHEs affect diabetes management, sleep quality, functioning, and to assess if these impacts differ by diabetes type or country. METHODS:An internet survey to adults with diabetes in th...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2011.624144

    authors: Brod M,Christensen T,Bushnell DM

    更新日期:2012-01-01 00:00:00

  • Compliance and persistence with Alzheimer's disease treatment: a retrospective analysis of multiregional hospital databases in Thailand.

    abstract::Aims: Due to the lack of studies evaluating compliance or persistence with Alzheimer's Disease (AD) treatment outside High-Income Countries (HICs), this study aimed to assess compliance, persistence, and factors associated with non-compliance and non-persistence by utilizing existing "real-world" information from mult...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1534739

    authors: Kongpakwattana K,Dilokthornsakul P,Dejthevaporn C,Pattanaprateep O,Chaiyakunapruk N

    更新日期:2019-01-01 00:00:00

  • Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.

    abstract:OBJECTIVE:This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS:A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apr...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1571500

    authors: Wu JJ,Pelletier C,Ung B,Tian M

    更新日期:2019-04-01 00:00:00

  • The economic burden of depression among adults with rheumatoid arthritis in the United States.

    abstract:AIMS:Depression is the most frequent comorbidity reported among patients with rheumatoid arthritis (RA). Comorbid depression negatively impacts RA patients' health-related quality-of-life, physical function, mental function, mortality, and experience of pain and symptom severity. The objective of this study was to asse...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1572015

    authors: Li N,Chan E,Peterson S

    更新日期:2019-04-01 00:00:00

  • Modelling the lifetime economic consequences of glaucoma in France.

    abstract:OBJECTIVE:To estimate the lifetime economic consequences of glaucoma in France. METHODS:A Markov model estimated the average discounted outcome and cost of glaucoma treatment over a patient's lifetime. Clinical states were defined as first- to fourth-line drugs, no treatment, laser therapy, surgery, blindness and deat...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990902728729

    authors: Philippe Nordmann J,Lafuma A,Berdeaux G

    更新日期:2009-03-01 00:00:00

  • The economic burden of chronic obstructive pulmonary disease from 2004 to 2013.

    abstract:OBJECTIVES:This study examines the epidemiology and economic impact of chronic obstructive pulmonary disease (COPD) at a nationwide level in South Korea. METHODS:This retrospective analysis used the societal cost-of-illness framework, consisting of direct medical costs, direct non-medical costs, and indirect costs. In...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1100114

    authors: Kim J,Lee TJ,Kim S,Lee E

    更新日期:2016-01-01 00:00:00

  • Cost effectiveness of palivizumab in children with congenital heart disease in Germany.

    abstract:OBJECTIVES:To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in infants with haemodynamically significant congenital heart disease (CHD) in the German healthcare setting. STUDY DESIG...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990903347172

    authors: Nuijten M,Lebmeier M,Wittenberg W

    更新日期:2009-01-01 00:00:00

  • Similar patient outcomes yet different hospital costs between flowable hemostatic agents.

    abstract:INTRODUCTION:SURGIFLO and FLOSEAL are absorbable gelatin-based products that form hemostatic matrices. These products are indicated as adjuncts to hemostasis when control of bleeding by conventional surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. This study analyzed the effect o...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1044994

    authors: David G,Lim S,Gunnarsson C,Kocharian R,Roy S

    更新日期:2015-01-01 00:00:00

  • Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.

    abstract:OBJECTIVE:The ECHELON-1 trial demonstrated efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as frontline therapy for stage III/IV classical Hodgkin lymphoma. This analysis evaluated the cost-effectiveness o...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/13696998.2018.1542599

    authors: Delea TE,Sharma A,Grossman A,Eichten C,Fenton K,Josephson N,Richhariya A,Moskowitz AJ

    更新日期:2019-02-01 00:00:00

  • Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.

    abstract:BACKGROUND AND OBJECTIVES:The cost effectiveness of pregabalin as an add-on to the standard treatment of Belgian patients with post-herpetic neuralgia (PHN) had been demonstrated in a previously published Markov model. The purpose of this study was to update that model with more recent cost data and clinical evidence, ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.773333

    authors: Chevalier P,Lamotte M,Van Campenhout H,Eyckerman R,Annemans L

    更新日期:2013-01-01 00:00:00

  • The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.

    abstract:INTRODUCTION:The patient cost burden of oral anticancer medicines has been associated with prescription abandonment, delayed treatment initiation, and poorer health outcomes in the US. Since 2011, several small molecule tyrosine kinase inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1580200

    authors: Seetasith A,Wong W,Tse J,Burudpakdee C

    更新日期:2019-05-01 00:00:00

  • A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation.

    abstract:OBJECTIVE:In patients with significant mitral regurgitation (MR) at high risk of mortality and morbidity from mitral valve surgery, transcatheter mitral valve repair with the MitraClip System is associated with a reduction in MR and improved quality-of-life and functional status compared with baseline. The objective wa...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.923892

    authors: Cameron HL,Bernard LM,Garmo VS,Hernandez JB,Asgar AW

    更新日期:2014-08-01 00:00:00

  • Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.

    abstract:BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.761633

    authors: Papadopoulos G,Hunt S,Prasad M

    更新日期:2013-01-01 00:00:00

  • Healthcare costs of pregnancy in systemic lupus erythematosus: retrospective observational analysis from a US health claims database.

    abstract:OBJECTIVE:Systemic lupus erythematosus is a complex autoimmune disease, most frequently affecting women of childbearing age. Women with lupus are at increased risk of pregnancy complications that are exacerbated by active disease. Despite this, their use of medications and hospital resources has not been extensively st...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1066796

    authors: Petri M,Daly RP,Pushparajah DS

    更新日期:2015-01-01 00:00:00

  • Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.

    abstract:OBJECTIVE:Few studies have examined the costs associated with differing first-line chemotherapy regimens in patients with metastatic breast cancer (MBC). This study compares the relative cost impact of women starting first-line chemotherapy with capecitabine versus taxanes. METHODS:Women receiving first-line chemother...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990903269673

    authors: Camacho FT,Wu J,Wei W,Kimmick G,Anderson RT,Balkrishnan R

    更新日期:2009-09-01 00:00:00

  • Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise.

    abstract:OBJECTIVE:The spectrum of diseases caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) represents a large burden on healthcare systems around the world. Meningitis, bacteraemia, community-acquired pneumonia (CAP), and acute otitis media (AOM) are vaccine-preventable infectious diseases tha...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2011.622323

    authors: Knerer G,Ismaila A,Pearce D

    更新日期:2012-01-01 00:00:00

  • The cost-effectiveness of somatropin treatment for short children born small for gestational age (SGA) and children with growth hormone deficiency (GHD) in Sweden.

    abstract:OBJECTIVE:Reduction in health-related quality of life is common in children born small for gestational age (SGA) or children with growth hormone deficiency (GHD). Growth hormone treatment with somatropin in these children leads to normalisation of height. The aim of this study was to determine whether somatropin is a c...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696991003652248

    authors: Christensen T,Fidler C,Bentley A,Djurhuus C

    更新日期:2010-03-01 00:00:00

  • Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.

    abstract:OBJECTIVE:To estimate the cost-effectiveness of ipilimumab (3 mg/kg) compared with best supportive care (BSC) in pre-treated advanced melanoma patients. METHODS:The analysis was based on a US payer perspective and lifetime time horizon. A three-state Markov model was developed representing clinical outcomes, quality-o...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.739226

    authors: Barzey V,Atkins MB,Garrison LP,Asukai Y,Kotapati S,Penrod JR

    更新日期:2013-01-01 00:00:00

  • Effectiveness of mobile application for menstrual management of working women in Japan: randomized controlled trial and medical economic evaluation.

    abstract:AIMS:Hormonal imbalances can affect a woman's physical and mental condition, impacting her daily life and productivity. A mobile application, "Karada-no-kimochi", predicts the menstrual cycle based on recorded data, and provides the information regarding menstruation. This study investigates the effectiveness of the ap...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/13696998.2018.1515082

    authors: Song M,Kanaoka H

    更新日期:2018-11-01 00:00:00

  • Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a.

    abstract:AIM:Disease-modifying therapies (DMTs) impact the natural history of relapsing forms of multiple sclerosis (RRMS) by reducing annual relapse rates and slowing disability progression. The effect of DMTs on indirect costs has not been consistently explored in cost-effectiveness studies thus far. The value to patients of ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1357564

    authors: Frasco MA,Shih T,Incerti D,Diaz Espinosa O,Vania DK,Thomas N

    更新日期:2017-10-01 00:00:00

  • Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view.

    abstract:OBJECTIVE:To quantify and compare hospital length of stay (LOS) and costs between hospitalized non-valvular atrial fibrillation (NVAF) patients treated with either apixaban or warfarin via a large claims database. METHODS:Adult patients hospitalized with AF were selected from the Premier Perspective Claims Database (0...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2016.1171774

    authors: Xie L,Vo L,Keshishian A,Price K,Singh P,Mardekian J,Bruno A,Baser O,Kim J,Tan W,Trocio J

    更新日期:2016-08-01 00:00:00

  • Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.

    abstract:OBJECTIVE:To evaluate total annual all-cause, gastrointestinal-related, and symptom-related healthcare costs among chronic constipation (CC) patients and estimate incremental all-cause healthcare costs of CC patients relative to matched controls. METHODS:Patients aged ≥18 years with continuous medical and pharmacy ben...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.860375

    authors: Cai Q,Buono JL,Spalding WM,Sarocco P,Tan H,Stephenson JJ,Carson RT,Doshi JA

    更新日期:2014-02-01 00:00:00

  • A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.

    abstract:AIM:The aim of this analysis was to investigate total healthcare costs, HbA1c, and weight changes over a 36-month period in patients with type 2 diabetes initiated on NPH or long-acting insulin analogs. METHODS:Electronic patient data from 479 general practices in the UK (THIN database) were examined for new users of ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.991788

    authors: Idris I,Gordon J,Tilling C,Vora J

    更新日期:2015-04-01 00:00:00

  • Healthcare costs of fast-acting insulin analogues versus short-acting human insulin for Danish patients with type 2 diabetes on a basal-bolus regimen.

    abstract:AIMS:Fast-acting insulin analogues (FAIAs) reduce hypoglycaemia and improve administration flexibility compared with short-acting human insulin (SHI). This analysis examines whether these benefits translate into cost offsets when comparing the total treatment costs for FAIA versus SHI used as basal-bolus therapy for tr...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2011.588892

    authors: Christensen TE,Gundgaard J,Pilgaard T

    更新日期:2011-01-01 00:00:00

  • Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.

    abstract:OBJECTIVE:To compare 1-year costs and benefits of dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, with those of other treatments for type 2 diabetes (T2D), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), sulfonylureas (SUs), thiazolidinediones (TZDs), and dipeptidyl peptidase-4 ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1434182

    authors: Chakravarty A,Rastogi M,Dhankhar P,Bell KF

    更新日期:2018-05-01 00:00:00

  • The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective.

    abstract:OBJECTIVE:A new and smaller percutaneous ventricular assist device (pVAD, Impella, Abiomed, Danvers, MA) has been developed to provide circulatory support in hemodynamically unstable patients and to prevent hemodynamic collapse during high-risk percutaneous coronary interventions (PCI). The objective of the study was t...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.762004

    authors: Roos JB,Doshi SN,Konorza T,Palacios I,Schreiber T,Borisenko OV,Henriques JP

    更新日期:2013-01-01 00:00:00

  • Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy.

    abstract:OBJECTIVE:Cost-effectiveness analyses of new treatments for cardiovascular disease frequently require input parameters whose values are known with uncertainty due to limited data. The objective of this paper is to examine the extent to which published sensitivity analyses addressing this uncertainty adhere to Health Te...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.3111/13696990903123813

    authors: Mauskopf JA,Boye KS,Schmitt C,McCollam P,Birt J,Juniper MD,Bakhai A

    更新日期:2009-06-01 00:00:00

  • A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs.

    abstract:OBJECTIVE:To compare outcomes between patients with type 2 diabetes mellitus (T2DM) using fixed-dose combination (FDC) and loose-dose combination (LDC) products. METHODS:This retrospective cohort study used MarketScan Commercial and Medicare Supplemental data from January 1, 2009-December 31, 2013. The identified popu...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1109518

    authors: Lokhandwala T,Smith N,Sternhufvud C,Sörstadius E,Lee WC,Mukherjee J

    更新日期:2016-01-01 00:00:00

  • Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.

    abstract:OBJECTIVES:To describe treatment patterns and healthcare burden among individuals with suspected pulmonary arterial hypertension (PAH), as identified through a practice guideline-based healthcare claims algorithm. METHODS:Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicar...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.690801

    authors: Copher R,Cerulli A,Watkins A,Laura Monsalvo M

    更新日期:2012-01-01 00:00:00

  • Comparison of historical medical spending patterns among the BRICS and G7.

    abstract:OBJECTIVE:The past few decades have been marked by a bold increase in national health spending across the globe. Rather successful health reforms in leading emerging markets such as BRICS reveal a reshaping of their medical care-related expenditures. There is a scarcity of evidence explaining differences in long-term m...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1093493

    authors: Jakovljevic MM

    更新日期:2016-01-01 00:00:00